Healthcare software developer and information provider Synigence has entered into a co-marketing agreement with Nasdaq-listed pharmaceutical group Quintiles Transnational. The deal grants Quintiles exclusive co-promotion rights to Synigence's health information and communication service Clinnix, which is aimed at GPs. In return, Quintiles' subsidiary PharmaBio has agreed to pay a premium price of 55p a share for 2,134,600 shares in the company.